Anti-diabetic medication used as slimming, Ema stops: “They’re helpful for sick folks” – Adnkronos

Antidiabetes slimming medication, Glp-1 receptor agonists, “has been within the information for the previous 2 years” and lots of could have “heard of them. Essentially the most briefly provide within the EU are Ozempic, Saxenda, Trulicity, Victoza and these medicines are in all places, from on-line discussions on social media to public statements by celebrities, and they’re changing into a part of of well-liked tradition, so we can not ignore that there’s a rise in off-label use by individuals who don’t have diabetes or weight problems and who see Glp agonists. -1 as a possible miracle drug for weight reduction. ” This off-label use should “cease.” That is the warning from Emer Cooke, govt director of the European Medicines Company EMA.

“As a pharmaceutical regulator – he defined at present at a press convention – now we have a job in managing shortages and that’s the reason now we have given suggestions at European stage for all actors to is concerned, to make sure that these medicines are for individuals who want them most. .”

“The continued excessive demand” for GLP-1 receptor antagonist anti-diabetic medication “has additionally attracted legal exercise, growing the danger of counterfeit merchandise getting into the market with antagonistic results on public well being,” the EMA mentioned.

From 2022, there was a rise within the demand for medication from this household. This improve in demand, together with different points equivalent to manufacturing capability limits, has led to shortages throughout the EU (and past).

“The EMA and a community of EU regulatory our bodies – we learn in a notice – are intently monitoring the scenario and taking numerous actions from 2022.” The suggestions of the MSSG group point out “the subsequent step within the coordinated response to present deficits.”